Patrick Decourcy

Patrick DeCourcy is a seasoned professional in program management with extensive experience in the biotechnology and pharmaceutical industries. Currently serving as Senior Director of Program Management at Intellia Therapeutics, Inc., Patrick leads the NTLA-2002 in vivo CRISPR gene therapy program, marking the first in vivo CRISPR gene therapy to enter pivotal Phase 3 studies. Prior roles include Director of Program Management at Arena Pharmaceuticals, overseeing late-stage drug development for atopic dermatitis, and extensive experience at Sanofi Genzyme, leading global medical operations and project management for Dupixent in dermatology and respiratory fields. Patrick's academic background includes an MBA and MS in Finance from Bentley University, an MS in Biotechnology from Worcester State University, and a BS in Biochemistry from the University of Massachusetts Amherst.